Tuesday, October 20, 2026, 11 AM-12 PM ET
Hear experts review the biological and clinical significance of the HER2 expression continuum in breast tissue, providing a clearer understanding of how these variations might impact diagnosis, and discuss the emerging importance of documenting HER2-low and HER2-ultralow categories using a validated IHC assay.
Webinar presenters Keith Wharton, MD, PhD, Global Medical Affairs Leader–Pathology, Roche Diagnostics Solutions, and Hannah Y. Wen, MD, PhD, Director, Breast Pathology Fellowship, Associate Team Leader, Breast Pathology Team, Attending Pathologist, Memorial Sloan Kettering Cancer Center
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Roche.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Thursday, October 29, 2026, 1 PM-2 PM ET
Hear an expert discuss the evolving role of PD-L1 testing in HNSCC and ovarian cancer.
Webinar presenter Georgios Deftereos, MD, Professor of Pathology, Associate Director of the Clinical Cancer Genomics Laboratory, Director of Molecular Cytopathology, University of California, San Francisco
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Agilent.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Tuesday, November 3, 2026, 1 PM-2 PM ET
Hear an expert discuss the challenges of detecting NRG1 fusions and how RNA-based testing can support more comprehensive fusion identification in clinical practice.
Webinar presenter Benjamin Weinberg, MD, Associate Professor of Medicine and Attending Physician
specializing in gastrointestinal medical oncology
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Diaceutics.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Monday, November 16, 2026, 12:30 PM-2 PM ET
Hear experts discuss a multidisciplinary approach to oncopathology for HER2
assessments for solid tumors in the absence of a companion diagnostic.
Webinar presenters Funda Meric-Bernstam, MD, Chair, Department of Investigational Cancer Therapeutics Medical Director, Institute for Personalized Cancer Therapy, The University of Texas MD Anderson Cancer Center, Houston, Texas, and Emina E. Torlakovic, MD, PhD, College of Medicine, University of Saskatchewan, Canadian Biomarker Quality Assurance, Saskatoon, Saskatchewan, Canada, and Carol Cheung, MD, PhD, JD, FRCPC, Deputy Director, Canadian Biomarker Quality, Assurance—Programme canadien d’assurance de la qualité des biomarqueurs
CAP TODAY does not endorse any of the products or services named within. This program is being sponsored by Daiichi Sankyo, Inc. and AstraZeneca. The speaker is being compensated for the presentation. The program is not CME accredited and may not be used for CME accreditation.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Webinar presenter John Farrell, MD, Director, Microbiology & Serology Labs, Chair & Medical Director, Infection Control & Prevention; OSF St. Francis Medical Center discusses the advantages of implementing metagenomic sequencing in your laboratory.
>
Webinar presenters John Fox, MD, MHA, Brian D. Piening, PhD, and Pierre Del Moral, PhD, MBA discuss how your lab can navigate TSO Comprehensive reimbursement by engaging with your payers, which tools to use and information to highlight during the billing processes.
Webinar presenters Melanie Pollan, PhD, Alan H. B. Wu, PhD, and Christopher DeFilippi, MD, discuss how the Atellica IM TnIH assay can be used to aid in offering rapid and accurate detection of AMI, helping lead to a faster diagnosis (versus contemporary Troponin assays); it can now also assist clinicians to identify future death and cardiovascular event risk based on the new prognosis indication for use.
Webinar presenters Gwen Clarke, MD, FRCPC, Hematopathology and Transfusion Medicine, Island Health, Victoria British Columbia Canada, and Clinical Professor, Department of Laboratory Medicine Pathology, University of Alberta, and Nancy Robitaille, MD, FRCPC, Vice-President, Transfusion Medicine, Héma-Québec, Montreal Canada Hematology-Oncology, CHU Sainte-Justine, Montreal, Canada and Clinical Professor, Department of Pediatrics, Université de Montréal discuss how advancements in non-invasive prenatal testing (NIPT) for fetal RHD are transforming targeted antenatal prophylaxis with RhIG.
Webinar presenter Pranil K. Chandra, DO, Senior Vice President, Chief Genomics Officer, PathGroup, explores pathogenic gene fusions as oncogenic drivers and actionable biomarkers in precision oncology, focusing on NRG1 fusions.
Webinar presenters Marilyn M. Bui, MD, PhD, FCAP, Professor of Pathology and Scientific Director of Analytic Microscopy Core, Moffitt Cancer Center, and Savitri Krishnamurthy, MD, Professor, Department of Pathology, The University of Texas MD Anderson Cancer Center, and Patricia M. Raciti, MD, Scientific Director, Early Clinical Development and Translational Research, J&J Innovative Medicine, and Sylvia L. Asa, MD, PhD, Consultant in Endocrine Pathology, University Hospitals Cleveland Medical Center, Professor of Pathology, Case Western Reserve University discuss evaluation and implementation of AI tools for clinical use.
Webinar presenters Pranil K. Chandra, DO, Senior Vice President, Chief Genomics Officer PathGroup, and Nayan J. Sarma, PhD, HCLD/CC (ABB), Associate Director of Molecular Oncology PathGroup, and Jeff Gregg, MD, Vice President Medical Affairs, Biofidelity, Professor of Pathology and Laboratory Medicine, University of Nevada School of Medicine, address the gaps and limitations of CGP by using innovative simplified genomic profiling solutions that work for challenging samples not analyzable by CGP.
